• 대한한방내과학회지
• /
• 제23권1호
• /
• pp.73-81
• /
• 2002

Objective : in order to be convinced of improvement in quality of life in allergic rhinitis patients, I observed clinically remedical effect of Quingbixiaoyanwan-Derivatives(淸鼻消炎丸) on allergic rhinitis with a questionnaire. Methods : We treated forty five allergic patients at the Nam Chun Oriental Medical Hospital from October, 2001 to January, 2002. They were treated with Quingbixiaoyanwan-Derivatives(淸鼻消炎丸), nasal cleansing solution and dietary treatment, and the health-related quality of life with a questionnaire. Results : 1. The gender proportion was twenty five males(55.6%) and twenty females(44.4%); seven teenagers (15.6%); ten patients in their 20s(22.2%); twenty patients in their 30S(44.4%); six patients in their 40s(13.3%); two patients in over 50s (4.4%) 2. The duration of the disease: 0 case within six months; three cases for six months to one year (6.6%); fourteen cases for one year to five years(31.1%); twenty six cases for over five years(62.2%) 3. Major symptoms; forty three cases for watery rhinorrhea (95.5%); thirty one caess for nasal itching(68.8%); 91.1 cases for sneezing(41.0%);thirty nine cases for nasal obstruction (86.6%); sixteen cases for difficulty in smelling(35.5%);seventeen postnasal drip(37.7%);three bloody rhinorrhea (6.6%);fourteen cases for headaches(31.1%); nine cases for eyelid itching (60.0%). 4. Seasonal Distribution: perennial allergic rhinitis occurred as follows: 55.6% in winter; 13.3% in fall; 11.1 % in spring;2.2% in summer. 5. Other combined allergic symptoms; sixteen cases for allergic conjunctives (37.8%); eight cases for sinus(17.8%);four cases for atopic dermatitis (8.9%); three cases for bronchial asthma(6.7%); sixteen cases for none(35.6%) 6. After a specific prescription of Quingbixiaoyanwan-Derivatives(淸鼻消炎丸), nasal cleansing solution and dietary therapy, the quality of life in allergic rhinitis patients was improved to 20.27%, which was significantly.(P<0.001) 7. The specific treatment did not affect GOT/GPT and BUN/Creatinine. 8. The specific treatment did not influence the level of total IgE serum significantly. Conclusions : Based on the above results, I have concluded that the specific treatment of Quingbixiaoyanwan-Derivatives(淸鼻消炎丸), nasal cleansing solution and dietary therapy can improve the quality of life in allergic rhinitis patients.

• 한방안이비인후피부과학회지
• /
• 제20권1호통권32호
• /
• pp.218-227
• /
• 2007

Objective : The purpose of this study is to investigate outpatients of hypersensitive rhinitis including allergic rhinitis who had visited to Hospital of Oriental Medicine. Method : We analyzed statistics study in 580 patients, who had visited to the Dept. of dermatology, ophthalmology & otorhinolayngology Hospital of Oriental Medicine Dongeui University from March, 1998 to December, 2006. Results : The results were as follows. 1. There is more male(53.28%) than femal(46.72%). The age distributions of patients showed highest in 20-29 years, followed by 10-19 years, 30-39 years in order. 2. The yearly distributions of patients showed highest in 2004, followed by 2001, 2005 in order. The seasonal distributions of patients showed highest in fall, followed by winter, summer, spring in order. The monthly distributions of patients showed highest in September, followed by August, October in order. 3. The distributions of number of times in treatment showed highest in 1-5 times. The distributions of duration of treatment showed highest in 1 week. In the treatment method, a major portion of treatment methods was acupuncture, followed by herbal medicine treatment, aroma therapy in order. 4. The Frequency of use of Prescriptions showed highest in Bojungikgi-Tanggami. The Frequency of use of Extract showed highest in Sochungryong-Tang. 5. The distribution of past history showed highest in Atopic dermatitis. The distribution of Rhinologic Complication showed highest in Paranasal sinusitis.

• Journal of Yeungnam Medical Science
• /
• 제7권1호
• /
• pp.105-112
• /
• 1990

저자들은 1988년 5월 1일부터 12월 31일까지 영남대학교 의과대학 부속병원 이비인후과에 내원한 알레르기성 비염환자 39명을 대상으로 Ketotifen 1일 투 2mg씩 8주동안 투여 한 뒤 재채기 발작, 수성비루, 비폐색, 비강내 이학적 소견, 효과 발현시기, 부작용 등을 관찰하여 다음과 같은 결과를 얻었다. 1) 전반적 개선도는 개선 이상이 66.7%, 약간 개선 이상이 87.2%로 유의한 증상의 호전이 있었다. 2) 증상별로 재채기 발작은 73.5%, 수성비루 71%, 비폐색 58%에서 증상의 호전이 있었으며 재채기 발작과 수성비루에 대해 더욱 효과적이었다. 3) 증상의 발현시기는 1주이내 35.7%, 2주이내 53.8%, 3주이내 66.7%, 4주이내 74.4%, 8주이내 87.2%로 나타냈다. 4) 비점막 소견의 유의한 호전은 없었다. 5) 부작용은 1례에서 경한 복통과 설사가 있어서 투약을 중지하였다. 이상과 같이 Ketotifen은 알레르기성 비염의 치료에 효과적이며 비교적 안전하게 사용할 수 있는 약제라고 생각할 수 있다.

• 동의생리병리학회지
• /
• 제16권2호
• /
• pp.397-402
• /
• 2002

Clinical studies were done treated with aroma therapy in 22cases of patients for suffering allergic rhinitis. who were treated at Dept of Oriental respiratory internal medicine in the Hospital of Taejeon University from January 2001 to May 2001. The results were as follows. 1. In distribution of sex & age. 45.5% of them were man, and 54.5% of them were woman. Of those who were attached, 2. In distribution of occupation, 59% of them were student, 18% of them were housewife, 18% of them were white color, 9% Of them were blue color. 3. In distribution of the period of the clinical history, under six months was 32%, under 1 year was 9%, under 3 years was 27%, over 3 years was 32%. 4. In distribution of the seasonal contributing factor, most of them were perenial allergic rhinitis, others generally started in spring or winter. 5. In distribution of past history, 59% of them are none, 18% of them are asthma, 18% of them are atopic dermatitis, 5% of them are allergic dermatitis. 6. In distribution of family history, 46% of them are none, 27% of them are sibling line, 18% of them are paternal line, 9% of them are maternal line. 7. In distribution of symptom, the ratio of sneezing was 90%, nasal discharge was 81 %, nasal obstruction was 46%, pruritus was 41 %, headache was 31%, asthma was 22%, digestion disorder was 18%, tears was 9%, nosebreeding was 5%. 8. In distribution of diagnosis in descending order, wind-cold evil was 5%, spleen-lung energy asthnia was 31 %, lung-kidney asthnia was 64%. 9. In distribution of Herb medicine treatment, Tonggyu-tang was the most, the second was hyunggaiyunyo-tang. 10 In emotional change of patients aroma-therapy, only 14% of them felt good. 11. The total remedial value of the 22 patients was revealed 32.9%. 12. In proportion to grow older, the remedial value were decreased. 13. In proportion to the period of the clinical history was longer, the remedial value were decreased.

• 한방안이비인후피부과학회지
• /
• 제27권4호
• /
• pp.58-66
• /
• 2014

Objectives : The purpose of this study was to investigate the clinical manifestations and influences of occupation, concomitant allergic diseases, various aggravating factors and seasonal changes for patients with dyshidrotic eczema. Methods : A total of 219 patients who showed clinical manifestations of dyshidrotic eczema were included in this study. We retrospectively reviewed the clinical characteristics of all the patients. Results : 1. Among 219 patients, there were 76 male patients (34.7%), 143 female patients (65.3%), male to female ratio was 1: 1.88. The average age of the patients at admission was $31.9{\pm}9.8$ years, had a lot of 20s and 30s the distribution. 2. The average of duration of the admission to the clinic after the onset was $4.01{\pm}4.42$ years. 3. Common accompaning diseases dyshidrotic eczema patients have were allergic rhinitis(87 cases), and atopic dermatitis(55 cases), sweating(45 cases), and asthma(10 cases) in order. 4. The most commonly occurring sites for dyshidrotic eczema patients are fingers(60.3%), palm(53.4%), dorsum of hand(19.2%) and nails(5.5%) in order. 5. The most commonly contacted materials for dyshidrotic eczema patients are water(130 cases), cosmetics(40 cases) and rubber gloves(34 cases) in order. The aggravating factors of dyshidrotic eczema patients are emotional stress(110 cases), fatty food(22 cases) and alcohol(22 cases) in order. 6. The number of patients showing seasonal changes in symptoms was 111. The season with the most severe symptom was summer with 76 cases, which was statistically significant. Conclusions : This study demonstrated the various clinical characteristics of Korean patients with dyshidrotic eczema.

• 대한임상검사과학회지
• /
• 제39권2호
• /
• pp.104-112
• /
• 2007

The purpose of this study was to evaluate the general features of allergic patients in northwestern Chungcheongnamdo who visited Soonchunhyang University Cheonan Hospital. The subjects in this study were 1692 suspected allergic patients. After their allergic symptoms were checked and a MAST-CLA test was conducted, the following results were obtained: 1. The mean age of the subjects was 23.1 years old. The male patients represented 56.2% and the female patients accounted for 43.8%. 1387 (82.0%) patients of those investigated suffered from allergic disease. 2. Among the 1387 patients, 1022 (73.7%) patients showed an increased total IgE level. The positive rate of those who were in their 40s (87.0%) was the highest, but their age made no difference to their positive rate of total IgE. 3. Concerning the positive rate for allergen specific antibody by age, those who were in their teens (73.5%) topped the list and similar in all age group except in their 40s. By gender, the positive rate of the male and female were 56.3% and 43.9% respectively. Regarding the positive rates by allergic disease, those who suffered from allergic rhinitis (60.4%) were most vulnerable, followed by the patients with allergic dermatitis (47.4%), with bronchial asthma (47.2%) and with urticaria (39.4%). 4. As for seasonal positive rates, they were most susceptible in April (77.2%) and May (71.1%). We discovered a significant difference according to seasons; Spring (60.1%), Winter (45.4%) and Summer (39.2%). 5. In case of Korean inhalent panel, the most dominant allergen-specific antibodies were "Cockroach mix" (31.1%), followed by "D. pteronyssius" (23.8%) and "Dog" (14.3%). In the event of food panel, the most popular allergen-specific antibodies were "D. farinae" (25.0%), followed by "D. pteronyssinus" (19.8%) and "Hose dust" (12.0%). 6. The residential type made no difference to the positive rates of "House dust", "Cockroach mix" and "Dog" as major antigen but compared with others, positive rates for "Tick" were somewhat higher in apartment buildings.

• 한국임상약학회지
• /
• 제16권1호
• /
• pp.34-39
• /
• 2006

Fexofenadine, one of selective histamine $H_1$ receptor antagonists, has been used for the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. The bioequivalence of two fexofenadine hydrochloride preparations, containing 120 mg fexofenadine hydrochloride, was evaluated according to the guidelines of Korea Food & Drug Administration(KFDA). The test product was Hanmi Fexofenadine Hydrochloride Tablet $120mg^{(R)}$ made by Hanmi Pharm. Co. and the reference product was Allegra Tablet $120mg^{(R)}$ made by Handok Parmaceuticals Co.. Twenty healthy male subjects were randomly divided into two groups and a $2{\times}2$ cross-over study was employed. After one tablet was orally administered, blood was taken at predetermined time intervals and the concentration of fexofenadine in plasma was determined using a validated HPLC method with fluorescence detector. Two pharmacokinetic parameters, $AUC_t\;and\;C_{max}$, were calculated and analyzed statistically for the evaluation of bioequivalence of the two products. Analysis of variance was carried out using logarithmically transformed parameter values. The 90% confidence intervals of $AUC_t\;and\;C_{max}$ were log $0.844{\sim}log$ 1.149 and log $0.833{\sim}log$ 1.109, respectively. These values were within the acceptable bioequivalence intervals of log 0.8 to log 1.25. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating that Hanmi Fexofenadine Hydrochloride Tablet 120 mg is bioequivalent to Allegra Tablet 120 mg.

• Journal of Pharmaceutical Investigation
• /
• 제36권1호
• /
• pp.53-58
• /
• 2006

Fexofenadine, one of selective histamine $H_1$ receptor antagonists, has been used for the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. The bioequivalence of two fexofenadine hydrochloride preparations, containing 180 mg fexofenadine hydrochloride, was evaluated according to the guidelines of Korea Food & Drug Administration (KFDA). The test product was Hanmi Fexofenadine Hydrochloride $Tablet^{\circledR}$ made by Hanmi Pharm. Co. and the reference product was Allegra $Tablet^{\circledR}$ made by Handok Parmaceuticals Co.. Twenty healthy male subjects were randomly divided into two groups and a $2\;{\time}\;2$ cross-over study was employed. After one tablet was orally administered, blood was taken at predetermined time intervals and the concentration of fexofenadine in plasma was determined using a validated HPLC method with fluorescence detector. Two pharmacokinetic parameters, $AUC_t$ and $C_{max}$, were calculated and analyzed statistically for the evaluation of bioequivalence of the two products. Analysis of variance was carried out using logarithmically transformed parameter values. The 90% confidence intervals of $AUC_t$ and $C_{max}$ were $log\;0.822{\sim}log \;1.142$ and $log\;0.848{\sim}log\;1.172$, respectively. These values were within the acceptable bioequivalence intervals of log 0.8 to log 1.25. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating that Hanmi Fexofenadine Hydrochloride Tablet is bioequivalent to Allegra Tablet.

• Bulletin of the Korean Chemical Society
• /
• 제28권4호
• /
• pp.613-618
• /
• 2007

Pollens are known to be an allergen. They penetrate human respiratory system, triggering a type of seasonal allergic rhinitis called pollen allergy (hey fever). The purpose of this study is to test two field-flow fractionation (FFF) techniques, gravitational FFF (GrFFF) and sedimentation FFF (SdFFF), for their applicability to sizecharacterization of micron-sized pollens. Both GrFFF and SdFFF are elution techniques, providing sequential elution of particles based on size. They allow the size distribution as well as the mean size of the sample to be determined from the elution time. In this study, GrFFF and SdFFF were used to determine the size distribution of Paper Mulberry and Bermuda Grass pollens. For the Paper Mulberry pollen, the mean size obtained by GrFFF is 12.7 μm, and agrees rather well with the OM data with the relative error of 8.0%. For the Bermuda Grass pollen, the mean size obtained by GrFFF is 32.6 μm with the relative error of 12.3%. The mean sizes determined by SdFFF are 12.4 (relative error = 10.1%) and 27.1 μm (relative error = 5.2%) for the Paper Mulberry and the Bermuda Grass pollen, respectively. Although SdFFF tends to yield more accurate size distribution due to lower band broadening under the field strength higher than 1 G, the sizes determined by GrFFF were not significantly different from those by SdFFF.

• Journal of Pharmaceutical Investigation
• /
• 제34권6호
• /
• pp.483-489
• /
• 2004

Fexofenadine HCl is non-sedating histamine H1 receptor antagonist that can be used for the treatment of seasonal allergic rhinitis. The objective of this study was to investigate whether the carriers of deformable liposomes can enhance the transepithelial permeability of fexofenadine HCl across the in vitro ALI human nasal monolayer model. Characterization of this model was achieved by bioelectric measurements and morphological studies. The passage 2 and 3 of cell monolayers exhibited the TEER value of $2852\;{\pm}\;482\;ohm\;{\times}\;cm^2$ on 11 days of seeding and maintained high TEER value for 5 days. The deformable liposome of fexofenadine HCl was prepared with phosphatidylcholine (PC) and cholic acid using extruder method. The mean particle size was about 200 nm and the maximum entrapment efficiency of 33.0% was obtained in the formulation of 1% PC and $100\;{\mu}g/ml$ fexofenadine HCl. The toxicity of the deformable liposome to human nasal monolayers was evaluated by MTT assay and TEER value change. MTT assay showed that it has no toxic effect on the nasal epithelial cells in 2-hour incubation when the PC concentration was below 1%. However, deformable liposome could not enhance the transepithelial permeability $(P_{app})$ and cellular uptake of fexofenadine HCl. In conclusion, the in vitro model could be used in nasal drug transport studies and evaluation of transepithelial permeability of formulations.